MMP2 Protein (AA 30-660)

Produktnummer ABIN8057040

Dieses Recombinant MMP2-Protein wird in Mammalian Cells produziert.

Kurzübersicht für MMP2 Protein (AA 30-660) (ABIN8057040)

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Protein-Typ: Recombinant

Spezies: Human

Quelle: Mammalian Cells

Applikation: Immunogen (Imm)

Reinheit: > 80 % as determined by reducing SDS-PAGE.

Produktdetails

Proteineigenschaft: AA 30-660

Verwendungszweck: Recombinant Human MMP-2 Protein(Halo Tag)

Sequenz: Ala30-Cys660

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1.0 EU/mg of the protein as determined by the LAL method

Biological Activity Comment: Not validated for activity

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with 5 % Trehalose and 5 % Mannitol.

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Haltbarkeit: 12 months

Antigendetails

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Andere Bezeichnung: MMP-2

Hintergrund: Gelatinase A,72 kDa type IV collagenase,Matrix metalloproteinase-2,TBE-1,Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.

Molekulargewicht:

Calculated MW: 103.3 kDa

Observed MW: 100-110 kDa

Gen-ID: 4313

UniProt: P08253

Pathways: Activation of Innate immune Response